Hermes Biosciences Secures Seed Funding to Advance Extracellular Vesicle Isolation Technology for Precision Medicine
核心洞察
Hermes Biosciences (搜索) raised seed funding led by Genoa Ventures (搜索) to commercialize its automated extracellular vesicle isolation platform by 2026.
The company's nanofiltration technology delivers up to 10 times more vesicles than ultracentrifugation while preserving vesicle integrity and molecular content.
Extracellular vesicles carry disease-specific molecular cargo that could transform early disease detection and therapeutic development across cancer and degenerative diseases.
Hermes Biosciences (搜索) announced the completion of a seed financing round led by Genoa Ventures (搜索), with participation from Paladin Capital Group (搜索) and Vertical Venture Partners (搜索), to advance its automated extracellular vesicle (EV) isolation platform toward commercial launch in 2026. The San Francisco-based life science tools company aims to address critical bottlenecks in EV research that have limited their clinical application despite significant therapeutic potential.
Revolutionary Technology Addresses Critical Research Bottleneck
The company's platform builds on nanofiltration technology invented by co-founder Utkan Demirci, PhD, a professor at Stanford University School of Medicine. The system isolates EVs with exceptionally high yield and purity through a fully automated workflow, delivering up to 10 times more vesicles than ultracentrifugation and other commercial platforms while preserving vesicle integrity and molecular content.
"EVs carry information that could fundamentally change how we detect and understand disease, but unlocking that value depends on being able to isolate and study them reliably," said Paco Cifuentes, PhD, CEO of Hermes Biosciences (搜索). "Our technology opens the door for the clinical and research community to use EVs as an analyte of choice, addressing the sensitivity shortcomings of circulating tumor DNA and proteins, especially for early disease detection and progression."
Targeting Unmet Clinical Needs
Extracellular vesicles are nano-scale cell-communication packets shed by living cells into blood, urine, and other biofluids. They carry highly specific molecular cargo that reflects cell state and disease biology, making them powerful analytes for understanding, diagnosing, and treating cancer, degenerative diseases, and conditions in regenerative medicine.
Despite their abundance, ubiquity, and molecular specificity driving significant interest across research and drug development, EV isolation remains a major bottleneck. Current methods are slow, inconsistent, and difficult to scale. Ultracentrifugation is cumbersome and poorly suited for clinical workflows, while column-based kits introduce variability and operational complexity.
Platform Enables High-Throughput Clinical Applications
The Hermes platform's hands-off, workflow-integrated design enables true high-throughput operation and supports the expanding use of EVs as clinical and translational assets. The benchtop system targets clinical researchers across academia, pharmaceutical companies, and clinical customers who require standardized, scalable workflows.
"The Hermes platform enables collaborators across translational research to tap into the molecular conversations between cells, revealing how cells grow, communicate, and drive disease progression," said Vikram Chaudhery, PhD, Partner at Genoa Ventures (搜索) and President of General Inception (搜索). "Through our venture studio, General Inception, we were able to help translate this breakthrough technology into a company with a great team, great science, and a clear opportunity for outsized impact in human health."
Strategic Investment and Development Timeline
Pre-seed capital and company formation support were provided by Genoa's venture studio, General Inception (搜索). The funding will support the delivery of Hermes' first commercial instrument in 2026, positioning the company to serve the growing demand for reliable EV isolation tools in precision medicine applications.
The technology provides high-quality exosome data for research, diagnostic development, and clinical innovation to support new approaches to detect, understand, and treat disease, with particular emphasis on early biomarker discovery and therapeutic development applications.